What's Happening?
The hereditary angioedema (HAE) market is anticipated to grow significantly, reaching USD 5.96 billion by 2032, according to Coherent Market Insights. This growth is driven by increased awareness of the
disorder and the introduction of advanced treatment options. Improved diagnostic tools, such as genetic testing, are enabling earlier and more accurate detection of HAE, expanding the patient base and increasing demand for effective therapies. The market is expected to be dominated by hereditary angioedema type I, which is projected to capture a revenue share of 67.8% in 2025. C1 esterase inhibitors remain the most popular drug class, accounting for 30.1% of the market share. North America is expected to lead the global market, while Asia Pacific is poised to become a lucrative region for HAE market companies.
Why It's Important?
The growth of the hereditary angioedema market is significant for several reasons. Firstly, the increased awareness and diagnosis of HAE are leading to more effective treatments reaching patients, improving their quality of life. The introduction of novel therapies, such as biologics and monoclonal antibodies, is creating new opportunities for market expansion. Additionally, the shift towards more patient-friendly administration routes, like oral therapies and subcutaneous injections, enhances patient adherence and convenience. However, high treatment costs and delayed diagnosis in some regions may limit market growth. The rapid approval of new treatments by regulatory agencies like the FDA is crucial in ensuring that effective therapies are available to patients sooner.
What's Next?
The hereditary angioedema market is expected to continue evolving with advancements in treatment options. Leading companies are developing novel therapies to prevent HAE attacks, such as KalVista Pharmaceuticals' plasma kallikrein inhibitor, which recently received FDA approval. The demand for long-term prophylactic treatments is increasing, which is likely to boost sales of HAE drugs. Regulatory agencies are supporting the industry by approving new treatments quickly, allowing them to reach patients faster. The adoption of AI-powered diagnostic tools for rare disease detection is expected to improve HAE patient identification rates, expanding the market size.
Beyond the Headlines
The hereditary angioedema market is witnessing a shift towards prophylactic treatments, which are expected to reduce the frequency and severity of HAE attacks. Oral on-demand treatments are gaining traction due to their convenience and rapid onset of action. The FDA's accelerated approval pathways for rare diseases are reducing development costs and time-to-market for HAE treatments. In-vivo gene editing clinical trials for HAE could disrupt the market with potential curative treatments, posing a threat to traditional prophylactic therapies. The digitalization of healthcare and telemedicine adoption are improving HAE patient identification rates, further expanding the market.
